SCHEMBL13487599

SCHEMBL13487599

CC1(C)c2ccccc2-c2cc(-c3c4ccccc4c(-c4ccncc4)c4ccc(-c5cccc6ccccc56)cc34)ccc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK11 Q15759 2/20 0.38
MAPK14 Q16539 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
MAPK1 P28482 1/20 0.38
RAB9A P51151 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MAPK13 O15264 1/20 0.35
GCGR P47871 1/20 0.35
MAPK12 P53778 1/20 0.35
ALOX5 P09917 1/20 0.34
TNF P01375 1/20 0.34
PDK2 Q15119 1/20 0.34
MCL1 Q07820 1/20 0.33
ACMSD Q8TDX5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13487972 0.93 PDK2 (0.39) MAPK11MAPK14SMN1; SMN2KDM4ENPC1
SCHEMBL13487605 0.89 CCNT1 (0.33) MAPK11MAPK14SMN1; SMN2KDM4ENPC1
SCHEMBL13487600 0.89 HTR2C (0.36) SMN1; SMN2KDM4ENPC1ALDH1A1LMNA
SCHEMBL13487656 0.89 MAPK9 (0.37) MAPK11MAPK14PDK2MAPK10HSD17B1
SCHEMBL13487174 0.89 MAPK11 (0.38) MAPK11MAPK14SMN1; SMN2KDM4ENPC1
SCHEMBL13487603 0.88 KDM4E (0.41) SMN1; SMN2KDM4ENPC1ALDH1A1MAPT
SCHEMBL13487604 0.88 PDK2 (0.33) SMN1; SMN2KDM4EALDH1A1MAPTHPGD
SCHEMBL13487616 0.88 TNF (0.40) MAPK11MAPK14SMN1; SMN2KDM4EALDH1A1
SCHEMBL13487590 0.88 PDK2 (0.33) MAPK11MAPK14KDM4EHPGDMAPK13
SCHEMBL13487720 0.87 PDK2 (0.43) MAPK14PDK2HSD17B1HSD17B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100045170-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-25 US disclosed
US-20100045170-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-25 US disclosed
EP-2108689-A2 Novel organic electroluminescent compounds and organic electroluminescent device using the same Gracel Display Inc. (KR) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100045170-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same OCIAD1, OCIAD2, ORMDL3 MAPK11 2795/4885MAPK14 3755/4885SMN1; SMN2 4002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.